The impact of body weight on rivaroxaban pharmacokinetics

Research and Practice in Thrombosis and Haemostasis

Volumn 1, Issue 2, 2017, Pages 180-187

  Barsam, Sarah J ^a   Patel, Jignesh P ^a,b   Roberts, Lara N ^a   Kavarthapu, Venu ^a   Patel, Raj K ^a   Green, Bruce ^c   Arya, Roopen ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Model Answers R D Pty Ltd   (Australia)

Author keywords

anticoagulation; obesity; pharmacokinetics; rivaroxaban; weight

Indexed keywords

CREATININE; ENOXAPARIN; RIVAROXABAN; WARFARIN;

ABSORPTION RATE CONSTANT; ADULT; AGED; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; COVARIANCE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SCREENING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGLAND; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; PHARMACOKINETICS; PRESCRIPTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL MODEL; TEACHING HOSPITAL; VENOUS THROMBOEMBOLISM; VOLUME OF DISTRIBUTION;

EID: 85047808132     PISSN: None     EISSN: 24750379     Source Type: Journal    
DOI: 10.1002/rth2.12039     Document Type: Article

References (32)

1. Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21:1–386.
2. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management and outcome of bleeding complications during rivaroxaban therapy in daily care: results from the Dresden NOAC registry. Blood. 2014;124:955–63.
3. Ageno W, Mantovani LG, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016;3:e12–21.
4. Camm AJ, Amarenco P, Haas S, et al.; on behalf of the Xantus Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145–53.
5. Patel JP, Couchman L, Chitongo PB, Flanagan RJ, Arya R. New anticoagulants: dosing and monitoring. BMJ. 2015;350:h1585.
6. Powell JR. Are new oral anticoagulant dosing recommendations optimal for all patients? JAMA. 2015;313:1013–4.
7. Bayer plc. Summary of product characteristics of rivaroxaban. 2016. http://www.medicines.org.uk/emc/medicine/25586 (accessed March 11, 2017).
8. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218–26.
9. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol. 2011;155:137–49.
10. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmocogen Genom. 2006;16:101–10.
11. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453–61.
12. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodyanamics of rivaroxaban – an oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203–16.
13. Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50:675–86.
14. Xu S, Moore K, Burton P, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol. 2012;74:86–97.
15. Di Nisio M, Vedovati MC, Riera-Mestre A, et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight – a sub-analysis of the Einstein DVT/PE studies. Thromb Haemost. 2016;116:739–46.
16. Arachillage DRJ, Reynolds R, Devey T, Maclean R, Kitchen S, van Veen JJ. Effects of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism. Thromb Res. 2016;147:32–5.
17. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–13.
18. National Institute for Clinical Excellence. TA 261 – Rivaroxaban for the treatment of DVT and prevention of recurrent DVT and PE, July 2012 [cited 2017 July 7]. Available from http://www.nice.org.uk/guidance/ta261.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
20. Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high resolution mass spectrometry. Ther Drug Monit. 2014;36:597–605.
21. Duffull SB, Wright DFB, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses – a clinical viewpoint. Br J Clin Pharmacol. 2011;71:807–14.
22. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984;15:153–71.
23. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991;32:669–70.
24. Davison AC, Hinkley DV. Bootstrap methods and their application. New York: Cambridge University Press; 1997.
25. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17–20.
26. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user's guides (1989–2009). Ellicott City, MD: Icon Development Solutions; 2009.
27. Keizer RJ, Jansen RS, Rosing H, Beijnen JH, Schellens JHM, Huitema ADR. Incorporation of extrapolated concentration data below the limit of quantification in population PK analyses. Presented as a poster at the Population Approach Group in Europe Annual Meeting, 2010. [cited 2017 July 2]. Available from http://www.page-meeting.org/?abstract=1722
28. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1–16.
29. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051–65.
30. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Ren Physiol. 2000;278:F817–22.
31. Han PY, Duffull SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82:505–8.
32. Kroll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. Br J Clin Pharmacol. 2017;83:1466–75.